Strategic partnerships Persist AI has active collaborations with Microsize and Micromacinazione to enable early-stage micromill formulation capabilities, presenting a sales angle to CROs and pharma partners seeking rapid, small-batch formulation testing and decision making.

Funding momentum Recent $12M Series A led by Spero Ventures with participation from Eli Lilly and others signals strong investor confidence and a growing platform that can scale partnerships, offering an opportunity to engage potential customers with funded pilots or co-development initiatives.

AI robotics platform The AI and robotics-powered Cloud Lab and automation stack targets shortening formulation discovery by 30-50%, enabling sales pitches around reduced cycle times, lower lab risk, and accelerated path to clinical and commercial manufacturing.

Regulatory and LAI potential Collaborations on long-acting injectable manufacturing and next-generation processes indicate a strategic fit for pharmaceutical manufacturers seeking scalable, AI-assisted LAI development, opening cross-sell opportunities into their broader manufacturing programs.

Market presence and traction Public announcements and media coverage in 2024–2026 demonstrate market validation and growing brand awareness, providing a credible entry point for outreach to pharma manufacturers, CROs, and contract manufacturing organizations evaluating advanced formulation tech.